Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii

Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins ar...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 60; no. 6; pp. 3480 - 3488
Main Authors Defraine, Valerie, Schuermans, Joris, Grymonprez, Barbara, Govers, Sander K., Aertsen, Abram, Fauvart, Maarten, Michiels, Jan, Lavigne, Rob, Briers, Yves
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.06.2016
Subjects
Online AccessGet full text
ISSN0066-4804
1098-6596
DOI10.1128/AAC.00285-16

Cover

Abstract Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii , even resulting in a complete elimination of large inocula (≥10 8 CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa , two of the most life-threatening pathogens of the order Pseudomonadales .
AbstractList Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula (≥10(8) CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa, two of the most life-threatening pathogens of the order Pseudomonadales.
Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula ( greater than or equal to 108 CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa, two of the most life-threatening pathogens of the order Pseudomonadales.
Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii , even resulting in a complete elimination of large inocula (≥10 8 CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa , two of the most life-threatening pathogens of the order Pseudomonadales .
Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However, Gram-negative pathogens are generally not susceptible due to their protective outer membrane. Artilysins overcome this barrier. Artilysins are optimized, engineered fusions of selected endolysins with specific outer membrane-destabilizing peptides. Artilysin Art-175 comprises a modified variant of endolysin KZ144 with an N-terminal fusion to SMAP-29. Previously, we have shown the high susceptibility of Pseudomonas aeruginosa to Art-175. Here, we report that Art-175 is highly bactericidal against stationary-phase cells of multidrug-resistant Acinetobacter baumannii, even resulting in a complete elimination of large inocula (≥108 CFU/ml). Besides actively dividing cells, Art-175 also kills persisters. Instantaneous killing of A. baumannii upon contact with Art-175 could be visualized after immobilization of the bacteria in a microfluidic flow cell. Effective killing of a cell takes place through osmotic lysis after peptidoglycan degradation. The killing rate is enhanced by the addition of 0.5 mM EDTA. No development of resistance to Art-175 under selection pressure and no cross-resistance with existing resistance mechanisms could be observed. In conclusion, Art-175 represents a highly active Artilysin against both A. baumannii and P. aeruginosa, two of the most life-threatening pathogens of the order Pseudomonadales.
Author Schuermans, Joris
Michiels, Jan
Briers, Yves
Lavigne, Rob
Grymonprez, Barbara
Govers, Sander K.
Fauvart, Maarten
Defraine, Valerie
Aertsen, Abram
Author_xml – sequence: 1
  givenname: Valerie
  surname: Defraine
  fullname: Defraine, Valerie
  organization: Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium
– sequence: 2
  givenname: Joris
  surname: Schuermans
  fullname: Schuermans, Joris
  organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium
– sequence: 3
  givenname: Barbara
  surname: Grymonprez
  fullname: Grymonprez, Barbara
  organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium
– sequence: 4
  givenname: Sander K.
  surname: Govers
  fullname: Govers, Sander K.
  organization: Laboratory of Food Microbiology, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium
– sequence: 5
  givenname: Abram
  surname: Aertsen
  fullname: Aertsen, Abram
  organization: Laboratory of Food Microbiology, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium
– sequence: 6
  givenname: Maarten
  surname: Fauvart
  fullname: Fauvart, Maarten
  organization: Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium
– sequence: 7
  givenname: Jan
  surname: Michiels
  fullname: Michiels, Jan
  organization: Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, KU Leuven, Heverlee, Belgium
– sequence: 8
  givenname: Rob
  surname: Lavigne
  fullname: Lavigne, Rob
  organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium
– sequence: 9
  givenname: Yves
  orcidid: 0000-0001-7723-1040
  surname: Briers
  fullname: Briers, Yves
  organization: Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Heverlee, Belgium, Laboratory of Applied Biotechnology, Department of Applied Biosciences, Ghent University, Ghent, Belgium
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27021321$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1rFTEUxYNU7GvrzrXMUqHTJjP53AjDo1ahoJTqNmQyd2rKTNImGeH99-b5WrGl4io5N78c7r3nAO354AGhNwSfENLI065bn2DcSFYT_gKtCFay5kzxPbTCmPOaSkz30UFKN7hopvArtN8I3JC2ISv0_WwcnTV2U4Wx6mJ20yY5v73VRLDKXBvnU64uIbmUjc-V8UP1FeJWQpGddR5y6I3NEKveLLPx3rkj9HI0U4LX9-ch-vbx7Gr9qb74cv553V3UhlGWa2ACBtkPQISiRDFKCbNSktYOQuC-x8qythRVTwWDgdieYjMwPsoWJHDVHqIPO9_bpZ9hsKWlaCZ9G91s4kYH4_TjF-9-6OvwU1MpVMtxMXh3bxDD3QIp69klC9NkPIQlaSKxFKRlrfg_KlTZKZOyKej7HWrS3OibsERftqAJ1tvIdIlM_45ME17Yt3-P8Kf3h4wK0OwAG0NKEUZtXTbZhe1EbvqX6_GTTw--z-K_AL5vsPY
CitedBy_id crossref_primary_10_1016_j_ijpharm_2020_119833
crossref_primary_10_1007_s10482_017_0912_9
crossref_primary_10_1080_1040841X_2020_1809346
crossref_primary_10_1111_1751_7915_13594
crossref_primary_10_1016_j_copbio_2020_08_014
crossref_primary_10_3390_foods14061075
crossref_primary_10_1128_CMR_00058_16
crossref_primary_10_1016_j_drup_2018_03_002
crossref_primary_10_1038_s41392_024_01866_5
crossref_primary_10_3390_microorganisms8060935
crossref_primary_10_1080_14787210_2016_1194754
crossref_primary_10_3390_antibiotics11111636
crossref_primary_10_1128_AAC_00024_19
crossref_primary_10_1039_D4MD00745J
crossref_primary_10_7554_eLife_98266_3
crossref_primary_10_1080_1040841X_2020_1822278
crossref_primary_10_1016_j_ijbiomac_2024_132990
crossref_primary_10_1080_17460913_2024_2393003
crossref_primary_10_1093_infdis_jiae027
crossref_primary_10_3390_v11030268
crossref_primary_10_1016_j_ejmech_2024_116381
crossref_primary_10_1038_srep35382
crossref_primary_10_31083_FBL24478
crossref_primary_10_3389_fmicb_2018_03302
crossref_primary_10_3390_antibiotics10121497
crossref_primary_10_3390_v12111286
crossref_primary_10_1007_s12223_023_01046_y
crossref_primary_10_1080_1040841X_2020_1825333
crossref_primary_10_1016_j_mib_2024_102433
crossref_primary_10_3390_v16050760
crossref_primary_10_1128_spectrum_01813_23
crossref_primary_10_1080_1040841X_2019_1600472
crossref_primary_10_7554_eLife_98266
crossref_primary_10_1007_s00203_024_04173_3
crossref_primary_10_3390_antibiotics7020029
crossref_primary_10_3389_fphar_2024_1385261
crossref_primary_10_1128_spectrum_04515_22
crossref_primary_10_3103_S0891416824700332
crossref_primary_10_1016_j_ijantimicag_2019_11_001
crossref_primary_10_3390_v17020200
crossref_primary_10_3389_fmicb_2018_00129
crossref_primary_10_3390_v15030679
crossref_primary_10_3390_antibiotics10030293
crossref_primary_10_1186_s13567_018_0563_5
crossref_primary_10_3390_v10040163
crossref_primary_10_3390_microorganisms12030629
crossref_primary_10_1021_acssynbio_7b00058
crossref_primary_10_3390_ph16091281
crossref_primary_10_1038_s41579_023_00993_0
crossref_primary_10_1016_j_molcel_2019_09_028
crossref_primary_10_4155_tde_2017_0040
crossref_primary_10_1016_j_biotechadv_2017_12_009
crossref_primary_10_1080_1040841X_2021_1939266
crossref_primary_10_1128_AAC_00836_17
crossref_primary_10_1007_s11262_020_01735_7
crossref_primary_10_1080_1040841X_2022_2125286
crossref_primary_10_36233_0372_9311_250
crossref_primary_10_3389_fcimb_2022_1035364
crossref_primary_10_1016_j_ijbiomac_2025_140463
crossref_primary_10_1016_j_micres_2021_126746
crossref_primary_10_1002_bit_28581
crossref_primary_10_3389_fmicb_2022_993990
crossref_primary_10_1080_1040841X_2023_2181056
crossref_primary_10_1126_sciadv_aaz1136
crossref_primary_10_1007_s00449_023_02938_6
crossref_primary_10_1016_j_pep_2018_12_002
crossref_primary_10_1007_s40121_021_00446_2
crossref_primary_10_1016_j_resmic_2023_104104
crossref_primary_10_1039_D1BM00423A
crossref_primary_10_3390_antibiotics10101260
crossref_primary_10_2174_1871526523666230511142054
crossref_primary_10_1146_annurev_virology_092917_043544
crossref_primary_10_3390_antibiotics9020074
crossref_primary_10_3389_fmicb_2023_1170418
crossref_primary_10_1093_femsre_fux001
crossref_primary_10_1016_S0140_6736_24_02081_6
crossref_primary_10_1111_1751_7915_14465
crossref_primary_10_3390_antibiotics12061044
crossref_primary_10_3389_fcimb_2017_00055
crossref_primary_10_1146_annurev_chembioeng_060816_101612
crossref_primary_10_1128_spectrum_05261_22
crossref_primary_10_1248_bpb_b19_00914
crossref_primary_10_3389_fimmu_2018_02252
crossref_primary_10_3389_fmicb_2018_01778
crossref_primary_10_1371_journal_pone_0192507
crossref_primary_10_1016_j_ijantimicag_2017_08_027
crossref_primary_10_1016_j_tibtech_2018_04_006
crossref_primary_10_1146_annurev_bioeng_010220_095711
crossref_primary_10_1111_1751_7915_14513
crossref_primary_10_1021_acsinfecdis_1c00222
crossref_primary_10_1128_aac_02273_21
crossref_primary_10_3389_fcimb_2016_00194
crossref_primary_10_1038_nrmicro_2017_61
crossref_primary_10_3390_pharmaceutics16121542
crossref_primary_10_3390_v11030284
crossref_primary_10_1016_j_drup_2016_10_002
crossref_primary_10_1007_s00284_021_02662_y
crossref_primary_10_1128_AEM_01515_21
Cites_doi 10.1128/AAC.04641-14
10.3389/fmicb.2014.00542
10.1111/2049-632X.12174
10.4103/0974-777X.68538
10.1371/journal.pgen.1003269
10.1128/AAC.01597-13
10.1038/nature07742
10.1128/AAC.01701-13
10.1016/j.ijantimicag.2013.04.022
10.1093/infdis/jit637
10.1016/j.bbapap.2008.11.005
10.2217/fmb.15.8
10.1002/ddr.20329
10.1128/CMR.05041-11
10.1086/595977
10.1128/JCM.00547-06
10.1371/journal.pone.0084361
10.1128/AAC.00243-13
10.1128/AAC.01966-15
10.1016/j.ijantimicag.2015.03.001
10.4161/viru.19700
10.1042/BST20120209
10.1016/S0966-842X(00)01705-4
10.2174/138920312804871193
10.1126/science.1211037
10.1038/nature01026
10.2217/fmb.12.97
10.1128/AAC.01783-12
10.1128/AAC.02668-14
10.1128/IAI.01600-14
10.1016/B978-0-12-394438-2.00007-4
10.1086/653120
10.1128/AAC.00860-09
10.1111/1462-2920.12594
10.1128/AAC.00633-13
10.1007/s00253-011-3104-y
10.1128/AEM.02440-10
10.1128/JB.01651-09
10.1146/annurev.micro.112408.134306
10.1126/science.1066869
10.1371/journal.pone.0104853
10.1586/eri.13.12
10.1128/MMBR.00016-10
10.1126/science.1229858
10.1080/21597081.2015.1062590
10.1016/j.ijmm.2010.04.002
10.1128/mBio.01379-14
10.1099/jmm.0.030932-0
ContentType Journal Article
Copyright Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology
Copyright_xml – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved.
– notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QL
7T7
8FD
C1K
FR3
P64
5PM
DOI 10.1128/AAC.00285-16
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Bacteriology Abstracts (Microbiology B)
Industrial and Applied Microbiology Abstracts (Microbiology A)
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Engineering Research Database
Technology Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Bacteriology Abstracts (Microbiology B)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList MEDLINE
Engineering Research Database
MEDLINE - Academic
CrossRef


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Art-175 against , Defraine et al
Art-175 against Acinetobacter baumannii
EISSN 1098-6596
EndPage 3488
ExternalDocumentID PMC4879360
00285-16
27021321
10_1128_AAC_00285_16
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Fund for Scientific Research-Flanders
  grantid: 1517115N
– fundername: Agency for Innovation by Science and Technology
– fundername: KU Leuven Research Council
  grantid: IDO/09/010
– fundername: Fund for Scientific Research-Flanders
  grantid: FWO G047112N
– fundername: KU Leuven Excellence Center Financing
  grantid: PF/2010/07
GroupedDBID ---
.55
.GJ
0R~
23M
2WC
39C
3O-
4.4
53G
5GY
5RE
5VS
6J9
AAGFI
AAYXX
ACGFO
ADBBV
AENEX
AGNAY
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HH5
HYE
HZ~
H~9
J5H
K-O
KQ8
L7B
LSO
MVM
NEJ
O9-
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UHB
VH1
W2D
W8F
WH7
WHG
WOQ
X7M
X7N
XOL
Y6R
ZGI
ZXP
~A~
CGR
CUY
CVF
ECM
EIF
NPM
-
0R
55
AAPBV
ABFLS
ADACO
BXI
HZ
RHF
ZA5
7X8
7QL
7T7
8FD
C1K
FR3
P64
5PM
ID FETCH-LOGICAL-a545t-e57ed8bde17941954415c8813cd770bb09c534419b475ed1cb40ad56f83e8e693
ISSN 0066-4804
IngestDate Thu Aug 21 14:00:17 EDT 2025
Fri Sep 05 04:57:47 EDT 2025
Fri Sep 05 10:11:13 EDT 2025
Tue Dec 28 13:59:19 EST 2021
Thu Apr 03 07:05:37 EDT 2025
Tue Jul 01 04:32:33 EDT 2025
Thu Apr 24 23:04:43 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Copyright © 2016, American Society for Microbiology. All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-a545t-e57ed8bde17941954415c8813cd770bb09c534419b475ed1cb40ad56f83e8e693
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Defraine V, Schuermans J, Grymonprez B, Govers SK, Aertsen A, Fauvart M, Michiels J, Lavigne R, Briers Y. 2016. Efficacy of Artilysin Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother 60:3480–3488. doi:10.1128/AAC.00285-16.
ORCID 0000-0001-7723-1040
OpenAccessLink https://aac.asm.org/content/aac/60/6/3480.full.pdf
PMID 27021321
PQID 1791325882
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4879360
proquest_miscellaneous_1808713537
proquest_miscellaneous_1791325882
asm2_journals_10_1128_AAC_00285_16
pubmed_primary_27021321
crossref_citationtrail_10_1128_AAC_00285_16
crossref_primary_10_1128_AAC_00285_16
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-06-01
PublicationDateYYYYMMDD 2016-06-01
PublicationDate_xml – month: 06
  year: 2016
  text: 2016-06-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Antimicrobial agents and chemotherapy
PublicationTitleAbbrev Antimicrob Agents Chemother
PublicationTitleAlternate Antimicrob Agents Chemother
PublicationYear 2016
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_3_50_2
Freimer EH (e_1_3_3_31_2) 1959; 110
e_1_3_3_16_2
e_1_3_3_18_2
e_1_3_3_39_2
e_1_3_3_12_2
e_1_3_3_37_2
e_1_3_3_14_2
e_1_3_3_35_2
e_1_3_3_33_2
e_1_3_3_10_2
e_1_3_3_40_2
e_1_3_3_5_2
e_1_3_3_7_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_29_2
e_1_3_3_23_2
e_1_3_3_48_2
e_1_3_3_25_2
e_1_3_3_46_2
e_1_3_3_44_2
e_1_3_3_3_2
e_1_3_3_21_2
e_1_3_3_42_2
e_1_3_3_17_2
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_32_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_6_2
e_1_3_3_8_2
e_1_3_3_28_2
e_1_3_3_49_2
e_1_3_3_24_2
e_1_3_3_47_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_4_2
e_1_3_3_22_2
e_1_3_3_41_2
23742833 - Int J Antimicrob Agents. 2013 Aug;42(2):141-8
22546906 - Virulence. 2012 May 1;3(3):243-50
10707065 - Trends Microbiol. 2000 Mar;8(3):120-8
19199531 - Infect Control Hosp Epidemiol. 2009 Mar;30(3):257-63
20927292 - J Glob Infect Dis. 2010 Sep;2(3):291-304
20504234 - Clin Infect Dis. 2010 Jul 1;51(1):79-84
20528688 - Annu Rev Microbiol. 2010;64:357-72
22096200 - Science. 2011 Nov 18;334(6058):982-6
20805405 - Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33
23629720 - Antimicrob Agents Chemother. 2013 Jul;57(7):3230-9
11739958 - Science. 2001 Dec 7;294(5549):2170-2
25857949 - Int J Antimicrob Agents. 2015 Jun;45(6):568-85
13824817 - J Exp Med. 1959 Dec 1;110:853-74
25360133 - Front Microbiol. 2014 Oct 16;5:542
23176506 - Biochem Soc Trans. 2012 Dec 1;40(6):1503-6
23483857 - PLoS Genet. 2013;9(2):e1003269
19100346 - Biochim Biophys Acta. 2009 May;1794(5):808-16
21459912 - J Med Microbiol. 2011 Jun;60(Pt 6):699-709
23305359 - Curr Protein Pept Sci. 2012 Dec;13(8):699-722
23030422 - Future Microbiol. 2012 Oct;7(10):1147-71
12192412 - Nature. 2002 Aug 22;418(6900):884-9
24100496 - Antimicrob Agents Chemother. 2013 Dec;57(12):6276-83
25142185 - Environ Microbiol. 2015 May;17(5):1586-99
19841146 - Antimicrob Agents Chemother. 2010 Jan;54(1):39-44
20452280 - Int J Med Microbiol. 2010 Aug;300(6):357-62
23288538 - Science. 2013 Jan 4;339(6115):91-5
26442196 - Bacteriophage. 2015 Jun 23;5(3):e1062590
22763634 - Clin Microbiol Rev. 2012 Jul;25(3):450-70
24752267 - Antimicrob Agents Chemother. 2014 Jul;58(7):3774-84
24189257 - Antimicrob Agents Chemother. 2014;58(1):518-26
25605353 - Antimicrob Agents Chemother. 2015 Apr;59(4):1983-91
25111143 - PLoS One. 2014 Aug 11;9(8):e104853
24987094 - MBio. 2014 Jul 01;5(4):e01379-14
25812461 - Future Microbiol. 2015;10(3):377-90
24391945 - PLoS One. 2013 Dec 31;8(12):e84361
19212404 - Nature. 2009 Feb 12;457(7231):849-53
16825400 - J Clin Microbiol. 2006 Jul;44(7):2630-4
24692291 - Pathog Dis. 2014 Jun;71(1):39-54
24891106 - Infect Immun. 2014 Aug;82(8):3417-25
21622798 - Appl Environ Microbiol. 2011 Jul;77(14):4878-85
23458769 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308
21264466 - Appl Microbiol Biotechnol. 2011 Apr;90(2):529-39
23229482 - Antimicrob Agents Chemother. 2013 Feb;57(2):1069-72
22748813 - Adv Virus Res. 2012;83:299-365
20935098 - J Bacteriol. 2010 Dec;192(23):6191-9
26574005 - Antimicrob Agents Chemother. 2015 Nov 16;60(1):592-9
24286983 - J Infect Dis. 2014 May 1;209(9):1469-78
23939892 - Antimicrob Agents Chemother. 2013 Nov;57(11):5239-46
Lafleur, MD, Qi, Q, Lewis, K (B46) 2010; 54
Nguyen, D, Joshi-Datar, A, Lepine, F, Bauerle, E, Olakanmi, O, Beer, K, McKay, G, Siehnel, R, Schafhauser, J, Wang, Y, Britigan, BE, Singh, PK (B8) 2011; 334
Cenens, W, Mebrhatu, MT, Makumi, A, Ceyssens, P-J, Lavigne, R, Van Houdt, R, Taddei, F, Aertsen, A (B18) 2013; 9
Tamma, PD, Cosgrove, SE, Maragakis, LL (B41) 2012; 25
Wakamoto, Y, Dhar, N, Chait, R, Schneider, K, Signorino-Gelo, F, Leibler, S, McKinney, JD (B9) 2013; 339
Freimer, EH, Krause, RM, McCarty, M (B30) 1959; 110
Lai, M-J, Soo, P-C, Lin, N-T, Hu, A, Chen, Y-J, Chen, L-K, Chang, K-C (B37) 2013; 42
Schuch, R, Lee, HM, Schneider, BC, Sauve, KL, Law, C, Khan, BK, Rotolo, JA, Horiuchi, Y, Couto, DE, Raz, A, Fischetti, VA, Huang, DB, Nowinski, RC, Wittekind, M (B42) 2014; 209
Potron, A, Poirel, L, Nordmann, P (B2) 2015; 45
Bhargava, N, Sharma, P, Capalash, N (B25) 2014; 82
Nelson, DC, Schmelcher, M, Rodriguez-Rubio, L, Klumpp, J, Pritchard, DG, Dong, S, Donovan, DM (B33) 2012; 83
Drulis-Kawa, Z, Majkowska-Skrobek, G, Maciejewska, B, Delattre, A-S, Lavigne, R (B29) 2012; 13
Fishbain, J, Peleg, AY (B40) 2010; 51
Lewis, K (B6) 2010; 64
Schmelcher, M, Donovan, DM, Loessner, MJ (B34) 2012; 7
Lood, R, Winer, BY, Pelzek, AJ, Diez-Martinez, R, Thandar, M, Euler, CW, Schuch, R, Fischetti, VA (B38) 2015; 59
Loeffler, JM (B48) 2001; 294
Manchanda, V, Sanchaita, S, Singh, N (B28) 2010; 2
Briers, Y, Walmagh, M, Van Puyenbroeck, V, Cornelissen, A, Cenens, W, Aertsen, A, Oliveira, H, Azeredo, J, Verween, G, Pirnay, J-P, Miller, S, Volckaert, G, Lavigne, R (B11) 2014; 5
Briers, Y, Lavigne, R (B13) 2015; 10
Merabishvili, M, Vandenheuvel, D, Kropinski, AM, Mast, J, De Vos, D, Verbeken, G, Noben, J-P, Lavigne, R, Vaneechoutte, M, Pirnay, J-P (B15) 2014; 9
Davies, J, Davies, D (B27) 2010; 74
Kim, DH, Choi, J-Y, Kim, HW, Kim, SH, Chung, DR, Peck, KR, Thamlikitkul, V, So, TM-K, Yasin, RMD, Hsueh, P-R, Carlos, CC, Hsu, LY, Buntaran, L, Lalitha, MK, Song, J-H, Ko, KS (B21) 2013; 57
Beceiro, A, Moreno, A, Fernandez, N, Vallejo, JA, Aranda, J, Adler, B, Harper, M, Boyce, JD, Bou, G (B19) 2014; 58
Fischetti, VA (B32) 2010; 300
Schuch, R, Nelson, D, Fischetti, VA (B49) 2002; 418
Oechslin, F, Daraspe, J, Giddey, M, Moreillon, P, Resch, G (B39) 2013; 57
Orman, MA, Brynildsen, MP (B7) 2013; 57
Yang, H, Yu, J, Wei, H (B31) 2014; 5
Barth, VC, Rodrigues, BÁ, Bonatto, GD, Gallo, SW, Pagnussatti, VE, Ferreira, CAS, de Oliveira, SD (B5) 2013; 8
Howard, A, O'Donoghue, M, Feeney, A, Sleator, RD (B23) 2012; 3
Valencia, R, Arroyo, LA, Conde, M, Aldana, JM, Torres, M-J, Fernandez-Cuenca, F, Garnacho-Montero, J, Cisneros, JM, Ortiz, C, Pachon, J, Aznar, J (B1) 2009; 30
Pendleton, JN, Gorman, SP, Gilmore, BF (B3) 2013; 11
Saule, M, Samuelsen, O, Dumpis, U, Sundsfjord, A, Karlsone, A, Balode, A, Miklasevics, E, Karah, N (B22) 2013; 57
Delcour, AH (B4) 2009; 1794
Liebens, V, Defraine, V, Van der Leyden, A, De Groote, VN, Fierro, C, Beullens, S, Verstraeten, N, Kint, C, Jans, A, Frangipani, E, Visca, P, Marchal, K, Versées, W, Fauvart, M, Michiels, J (B17) 2014; 71
Lai, M-J, Lin, N-T, Hu, A, Soo, P-C, Chen, L-K, Chen, L-H, Chang, K-C (B36) 2011; 90
Turton, JF, Kaufmann, ME, Gill, MJ, Pike, R, Scott, PT, Fishbain, J, Craft, D, Deye, G, Riddell, S, Lindler, LE, Pitt, TL (B24) 2006; 44
Chen, X, Zhang, M, Zhou, C, Kallenbach, NR, Ren, D (B16) 2011; 77
Roach, DR, Donovan, DM (B35) 2015; 5
Young, I, Wang, I, Roof, WD (B12) 2000; 8
Leaver, M, Dominguez-Cuevas, P, Coxhead, JM, Daniel, RA, Errington, J (B44) 2009; 457
Fauvart, M, De Groote, VN, Michiels, J (B10) 2011; 60
Dawson, RM, Liu, C-Q (B26) 2009; 70
Briers, Y, Walmagh, M, Grymonprez, B, Biebl, M, Pirnay, JP, Defraine, V, Michiels, J, Cenens, W, Aertsen, A, Miller, S, Lavigne, R (B14) 2014; 58
Cambré, A, Zimmermann, M, Sauer, U, Vivijs, B, Cenens, W, Michiels, CW, Aertsen, A, Loessner, MJ, Noben, J-P, Ayala, JA, Lavigne, R, Briers, Y (B45) 2015; 17
Oddo, A, Thomsen, TT, Kjelstrup, S, Gorey, C, Franzyk, H, Frimodt-Moller, N, Lobner-Olesen, A, Hansen, PR (B20) 2016; 60
Lukacik, P, Barnard, TJ, Buchanan, SK (B43) 2012; 40
Mulcahy, LR, Burns, JL, Lory, S, Lewis, K (B47) 2010; 192
References_xml – ident: e_1_3_3_39_2
  doi: 10.1128/AAC.04641-14
– ident: e_1_3_3_32_2
  doi: 10.3389/fmicb.2014.00542
– ident: e_1_3_3_18_2
  doi: 10.1111/2049-632X.12174
– ident: e_1_3_3_29_2
  doi: 10.4103/0974-777X.68538
– ident: e_1_3_3_19_2
  doi: 10.1371/journal.pgen.1003269
– ident: e_1_3_3_20_2
  doi: 10.1128/AAC.01597-13
– ident: e_1_3_3_45_2
  doi: 10.1038/nature07742
– ident: e_1_3_3_40_2
  doi: 10.1128/AAC.01701-13
– ident: e_1_3_3_38_2
  doi: 10.1016/j.ijantimicag.2013.04.022
– ident: e_1_3_3_43_2
  doi: 10.1093/infdis/jit637
– ident: e_1_3_3_5_2
  doi: 10.1016/j.bbapap.2008.11.005
– ident: e_1_3_3_14_2
  doi: 10.2217/fmb.15.8
– ident: e_1_3_3_27_2
  doi: 10.1002/ddr.20329
– ident: e_1_3_3_42_2
  doi: 10.1128/CMR.05041-11
– ident: e_1_3_3_2_2
  doi: 10.1086/595977
– ident: e_1_3_3_25_2
  doi: 10.1128/JCM.00547-06
– ident: e_1_3_3_6_2
  doi: 10.1371/journal.pone.0084361
– ident: e_1_3_3_8_2
  doi: 10.1128/AAC.00243-13
– ident: e_1_3_3_21_2
  doi: 10.1128/AAC.01966-15
– ident: e_1_3_3_3_2
  doi: 10.1016/j.ijantimicag.2015.03.001
– ident: e_1_3_3_24_2
  doi: 10.4161/viru.19700
– ident: e_1_3_3_44_2
  doi: 10.1042/BST20120209
– ident: e_1_3_3_13_2
  doi: 10.1016/S0966-842X(00)01705-4
– ident: e_1_3_3_30_2
  doi: 10.2174/138920312804871193
– ident: e_1_3_3_9_2
  doi: 10.1126/science.1211037
– ident: e_1_3_3_50_2
  doi: 10.1038/nature01026
– ident: e_1_3_3_35_2
  doi: 10.2217/fmb.12.97
– volume: 110
  start-page: 853
  year: 1959
  ident: e_1_3_3_31_2
  article-title: Studies of L forms and protoplasts of group A streptococci. I
  publication-title: Isolation, growth, and bacteriologic characteristics. J Exp Med
– ident: e_1_3_3_23_2
  doi: 10.1128/AAC.01783-12
– ident: e_1_3_3_15_2
  doi: 10.1128/AAC.02668-14
– ident: e_1_3_3_26_2
  doi: 10.1128/IAI.01600-14
– ident: e_1_3_3_34_2
  doi: 10.1016/B978-0-12-394438-2.00007-4
– ident: e_1_3_3_41_2
  doi: 10.1086/653120
– ident: e_1_3_3_47_2
  doi: 10.1128/AAC.00860-09
– ident: e_1_3_3_46_2
  doi: 10.1111/1462-2920.12594
– ident: e_1_3_3_22_2
  doi: 10.1128/AAC.00633-13
– ident: e_1_3_3_37_2
  doi: 10.1007/s00253-011-3104-y
– ident: e_1_3_3_17_2
  doi: 10.1128/AEM.02440-10
– ident: e_1_3_3_48_2
  doi: 10.1128/JB.01651-09
– ident: e_1_3_3_7_2
  doi: 10.1146/annurev.micro.112408.134306
– ident: e_1_3_3_49_2
  doi: 10.1126/science.1066869
– ident: e_1_3_3_16_2
  doi: 10.1371/journal.pone.0104853
– ident: e_1_3_3_4_2
  doi: 10.1586/eri.13.12
– ident: e_1_3_3_28_2
  doi: 10.1128/MMBR.00016-10
– ident: e_1_3_3_10_2
  doi: 10.1126/science.1229858
– ident: e_1_3_3_36_2
  doi: 10.1080/21597081.2015.1062590
– ident: e_1_3_3_33_2
  doi: 10.1016/j.ijmm.2010.04.002
– ident: e_1_3_3_12_2
  doi: 10.1128/mBio.01379-14
– ident: e_1_3_3_11_2
  doi: 10.1099/jmm.0.030932-0
– reference: 25812461 - Future Microbiol. 2015;10(3):377-90
– reference: 23305359 - Curr Protein Pept Sci. 2012 Dec;13(8):699-722
– reference: 23030422 - Future Microbiol. 2012 Oct;7(10):1147-71
– reference: 10707065 - Trends Microbiol. 2000 Mar;8(3):120-8
– reference: 20528688 - Annu Rev Microbiol. 2010;64:357-72
– reference: 22096200 - Science. 2011 Nov 18;334(6058):982-6
– reference: 21622798 - Appl Environ Microbiol. 2011 Jul;77(14):4878-85
– reference: 16825400 - J Clin Microbiol. 2006 Jul;44(7):2630-4
– reference: 24100496 - Antimicrob Agents Chemother. 2013 Dec;57(12):6276-83
– reference: 23939892 - Antimicrob Agents Chemother. 2013 Nov;57(11):5239-46
– reference: 24391945 - PLoS One. 2013 Dec 31;8(12):e84361
– reference: 22748813 - Adv Virus Res. 2012;83:299-365
– reference: 25142185 - Environ Microbiol. 2015 May;17(5):1586-99
– reference: 25360133 - Front Microbiol. 2014 Oct 16;5:542
– reference: 19199531 - Infect Control Hosp Epidemiol. 2009 Mar;30(3):257-63
– reference: 24752267 - Antimicrob Agents Chemother. 2014 Jul;58(7):3774-84
– reference: 25857949 - Int J Antimicrob Agents. 2015 Jun;45(6):568-85
– reference: 19100346 - Biochim Biophys Acta. 2009 May;1794(5):808-16
– reference: 20935098 - J Bacteriol. 2010 Dec;192(23):6191-9
– reference: 13824817 - J Exp Med. 1959 Dec 1;110:853-74
– reference: 19841146 - Antimicrob Agents Chemother. 2010 Jan;54(1):39-44
– reference: 20805405 - Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33
– reference: 21459912 - J Med Microbiol. 2011 Jun;60(Pt 6):699-709
– reference: 20504234 - Clin Infect Dis. 2010 Jul 1;51(1):79-84
– reference: 22763634 - Clin Microbiol Rev. 2012 Jul;25(3):450-70
– reference: 23288538 - Science. 2013 Jan 4;339(6115):91-5
– reference: 24987094 - MBio. 2014 Jul 01;5(4):e01379-14
– reference: 23229482 - Antimicrob Agents Chemother. 2013 Feb;57(2):1069-72
– reference: 20927292 - J Glob Infect Dis. 2010 Sep;2(3):291-304
– reference: 23742833 - Int J Antimicrob Agents. 2013 Aug;42(2):141-8
– reference: 20452280 - Int J Med Microbiol. 2010 Aug;300(6):357-62
– reference: 25111143 - PLoS One. 2014 Aug 11;9(8):e104853
– reference: 23483857 - PLoS Genet. 2013;9(2):e1003269
– reference: 24692291 - Pathog Dis. 2014 Jun;71(1):39-54
– reference: 21264466 - Appl Microbiol Biotechnol. 2011 Apr;90(2):529-39
– reference: 24891106 - Infect Immun. 2014 Aug;82(8):3417-25
– reference: 23629720 - Antimicrob Agents Chemother. 2013 Jul;57(7):3230-9
– reference: 23176506 - Biochem Soc Trans. 2012 Dec 1;40(6):1503-6
– reference: 12192412 - Nature. 2002 Aug 22;418(6900):884-9
– reference: 19212404 - Nature. 2009 Feb 12;457(7231):849-53
– reference: 25605353 - Antimicrob Agents Chemother. 2015 Apr;59(4):1983-91
– reference: 26574005 - Antimicrob Agents Chemother. 2015 Nov 16;60(1):592-9
– reference: 11739958 - Science. 2001 Dec 7;294(5549):2170-2
– reference: 22546906 - Virulence. 2012 May 1;3(3):243-50
– reference: 23458769 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308
– reference: 24286983 - J Infect Dis. 2014 May 1;209(9):1469-78
– reference: 26442196 - Bacteriophage. 2015 Jun 23;5(3):e1062590
– reference: 24189257 - Antimicrob Agents Chemother. 2014;58(1):518-26
– volume: 300
  start-page: 357
  year: 2010
  end-page: 362
  ident: B32
  article-title: Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens
  publication-title: Int J Med Microbiol
  doi: 10.1016/j.ijmm.2010.04.002
– volume: 10
  start-page: 377
  year: 2015
  end-page: 390
  ident: B13
  article-title: Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria
  publication-title: Future Microbiol
  doi: 10.2217/fmb.15.8
– volume: 57
  start-page: 5239
  year: 2013
  end-page: 5246
  ident: B21
  article-title: Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00633-13
– volume: 7
  start-page: 1147
  year: 2012
  end-page: 1171
  ident: B34
  article-title: Bacteriophage endolysins as novel antimicrobials
  publication-title: Future Microbiol
  doi: 10.2217/fmb.12.97
– volume: 57
  start-page: 6276
  year: 2013
  end-page: 6283
  ident: B39
  article-title: In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01701-13
– volume: 418
  start-page: 884
  year: 2002
  end-page: 889
  ident: B49
  article-title: A bacteriolytic agent that detects and kills Bacillus anthracis
  publication-title: Nature
  doi: 10.1038/nature01026
– volume: 82
  start-page: 3417
  year: 2014
  end-page: 3425
  ident: B25
  article-title: Pyocyanin stimulates quorum sensing-mediated tolerance to oxidative stress and increases persister cell populations in Acinetobacter baumannii
  publication-title: Infect Immun
  doi: 10.1128/IAI.01600-14
– volume: 77
  start-page: 4878
  year: 2011
  end-page: 4885
  ident: B16
  article-title: Control of bacterial persister cells by Trp/Arg-containing antimicrobial peptides
  publication-title: Appl Environ Microbiol
  doi: 10.1128/AEM.02440-10
– volume: 44
  start-page: 2630
  year: 2006
  end-page: 2634
  ident: B24
  article-title: Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00547-06
– volume: 83
  start-page: 299
  year: 2012
  end-page: 365
  ident: B33
  article-title: Endolysins as antimicrobials
  publication-title: Adv Virus Res
  doi: 10.1016/B978-0-12-394438-2.00007-4
– volume: 457
  start-page: 849
  year: 2009
  end-page: 853
  ident: B44
  article-title: Life without a wall or division machine in Bacillus subtilis
  publication-title: Nature
  doi: 10.1038/nature07742
– volume: 71
  start-page: 39
  year: 2014
  end-page: 54
  ident: B17
  article-title: A putative de-N-acetylase of the PIG-L superfamily affects fluoroquinolone tolerance in Pseudomonas aeruginosa
  publication-title: Pathog Dis
  doi: 10.1111/2049-632X.12174
– volume: 57
  start-page: 3230
  year: 2013
  end-page: 3239
  ident: B7
  article-title: Dormancy is not necessary or sufficient for bacterial persistence
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00243-13
– volume: 110
  start-page: 853
  year: 1959
  end-page: 874
  ident: B30
  article-title: Studies of L forms and protoplasts of group A streptococci. I
  publication-title: Isolation, growth, and bacteriologic characteristics. J Exp Med
– volume: 5
  start-page: e1062590
  year: 2015
  ident: B35
  article-title: Antimicrobial bacteriophage-derived proteins and therapeutic applications
  publication-title: Bacteriophage
  doi: 10.1080/21597081.2015.1062590
– volume: 1794
  start-page: 808
  year: 2009
  end-page: 816
  ident: B4
  article-title: Outer membrane permeability and antibiotic resistance
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbapap.2008.11.005
– volume: 5
  start-page: e01379-14
  year: 2014
  ident: B11
  article-title: Engineered endolysin-based “artilysins” to combat multidrug-resistant gram-negative pathogens
  publication-title: mBio
  doi: 10.1128/mBio.01379-14
– volume: 9
  start-page: e1003269
  year: 2013
  ident: B18
  article-title: Expression of a novel P22 ORFan gene reveals the phage carrier state in Salmonella typhimurium
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1003269
– volume: 334
  start-page: 982
  year: 2011
  end-page: 986
  ident: B8
  article-title: Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria
  publication-title: Science
  doi: 10.1126/science.1211037
– volume: 60
  start-page: 699
  year: 2011
  end-page: 709
  ident: B10
  article-title: Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies
  publication-title: J Med Microbiol
  doi: 10.1099/jmm.0.030932-0
– volume: 51
  start-page: 79
  year: 2010
  end-page: 84
  ident: B40
  article-title: Treatment of Acinetobacter infections
  publication-title: Clin Infect Dis
  doi: 10.1086/653120
– volume: 70
  start-page: 481
  year: 2009
  end-page: 498
  ident: B26
  article-title: Cathelicidin peptide SMAP-29: comprehensive review of its properties and potential as a novel class of antibiotics
  publication-title: Drug Dev Res
  doi: 10.1002/ddr.20329
– volume: 57
  start-page: 1069
  year: 2013
  end-page: 1072
  ident: B22
  article-title: Dissemination of a carbapenem-resistant Acinetobacter baumannii strain belonging to international clone II/sequence type 2 and harboring a novel AbaR4-like resistance island in Latvia
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01783-12
– volume: 42
  start-page: 141
  year: 2013
  end-page: 148
  ident: B37
  article-title: Identification and characterisation of the putative phage-related endolysins through full genome sequence analysis in Acinetobacter baumannii ATCC 17978
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2013.04.022
– volume: 9
  start-page: e104853
  year: 2014
  ident: B15
  article-title: Characterization of newly isolated lytic bacteriophages active against Acinetobacter baumannii
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0104853
– volume: 8
  start-page: e84361
  year: 2013
  ident: B5
  article-title: Heterogeneous persister cells formation in Acinetobacter baumannii
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0084361
– volume: 2
  start-page: 291
  year: 2010
  end-page: 304
  ident: B28
  article-title: Multidrug resistant Acinetobacter
  publication-title: J Glob Infect Dis
  doi: 10.4103/0974-777X.68538
– volume: 294
  start-page: 2170
  year: 2001
  end-page: 2172
  ident: B48
  article-title: Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase
  publication-title: Science
  doi: 10.1126/science.1066869
– volume: 13
  start-page: 699
  year: 2012
  end-page: 722
  ident: B29
  article-title: Learning from bacteriophages—advantages and limitations of phage and phage-encoded protein applications
  publication-title: Curr Protein Pept Sci
  doi: 10.2174/138920312804871193
– volume: 25
  start-page: 450
  year: 2012
  end-page: 470
  ident: B41
  article-title: Combination therapy for treatment of infections with gram-negative bacteria
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.05041-11
– volume: 58
  start-page: 3774
  year: 2014
  end-page: 3784
  ident: B14
  article-title: Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.02668-14
– volume: 90
  start-page: 529
  year: 2011
  end-page: 539
  ident: B36
  article-title: Antibacterial activity of Acinetobacter baumannii phage varphiAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-011-3104-y
– volume: 209
  start-page: 1469
  year: 2014
  end-page: 1478
  ident: B42
  article-title: Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jit637
– volume: 54
  start-page: 39
  year: 2010
  end-page: 44
  ident: B46
  article-title: Patients with long-term oral carriage harbor high-persister mutants of Candida albicans
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00860-09
– volume: 60
  start-page: 592
  year: 2016
  end-page: 599
  ident: B20
  article-title: An all-D amphipathic undecapeptide shows promising activity against colistin-resistant strains of Acinetobacter baumannii and a dual mode of action
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01966-15
– volume: 74
  start-page: 417
  year: 2010
  end-page: 433
  ident: B27
  article-title: Origins and evolution of antibiotic resistance
  publication-title: Microbiol Mol Biol Rev
  doi: 10.1128/MMBR.00016-10
– volume: 5
  start-page: 542
  year: 2014
  ident: B31
  article-title: Engineered bacteriophage lysins as novel anti-infectives
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2014.00542
– volume: 3
  start-page: 243
  year: 2012
  end-page: 250
  ident: B23
  article-title: Acinetobacter baumannii: an emerging opportunistic pathogen
  publication-title: Virulence
  doi: 10.4161/viru.19700
– volume: 58
  start-page: 518
  year: 2014
  end-page: 526
  ident: B19
  article-title: Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01597-13
– volume: 64
  start-page: 357
  year: 2010
  end-page: 372
  ident: B6
  article-title: Persister cells
  publication-title: Annu Rev Microbiol
  doi: 10.1146/annurev.micro.112408.134306
– volume: 59
  start-page: 1983
  year: 2015
  end-page: 1991
  ident: B38
  article-title: Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.04641-14
– volume: 45
  start-page: 568
  year: 2015
  end-page: 585
  ident: B2
  article-title: Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2015.03.001
– volume: 192
  start-page: 6191
  year: 2010
  end-page: 6199
  ident: B47
  article-title: Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis
  publication-title: J Bacteriol
  doi: 10.1128/JB.01651-09
– volume: 40
  start-page: 1503
  year: 2012
  end-page: 1506
  ident: B43
  article-title: Using a bacteriocin structure to engineer a phage lysin that targets Yersinia pestis
  publication-title: Biochem Soc Trans
  doi: 10.1042/BST20120209
– volume: 30
  start-page: 257
  year: 2009
  end-page: 263
  ident: B1
  article-title: Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital
  publication-title: Infect Control Hosp Epidemiol
  doi: 10.1086/595977
– volume: 8
  start-page: 120
  year: 2000
  end-page: 128
  ident: B12
  article-title: Phages will out: strategies of host cell lysis
  publication-title: Trends Microbiol
  doi: 10.1016/S0966-842X(00)01705-4
– volume: 11
  start-page: 297
  year: 2013
  end-page: 308
  ident: B3
  article-title: Clinical relevance of the ESKAPE pathogens
  publication-title: Expert Rev Anti Infect Ther
  doi: 10.1586/eri.13.12
– volume: 17
  start-page: 1586
  year: 2015
  end-page: 1599
  ident: B45
  article-title: Metabolite profiling and peptidoglycan analysis of transient cell wall-deficient bacteria in a new Escherichia coli model system
  publication-title: Environ Microbiol
  doi: 10.1111/1462-2920.12594
– volume: 339
  start-page: 91
  year: 2013
  end-page: 95
  ident: B9
  article-title: Dynamic persistence of antibiotic-stressed mycobacteria
  publication-title: Science
  doi: 10.1126/science.1229858
SSID ssj0006590
Score 2.535563
Snippet Bacteriophage-encoded endolysins have shown promise as a novel class of antibacterials with a unique mode of action, i.e., peptidoglycan degradation. However,...
SourceID pubmedcentral
proquest
asm2
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 3480
SubjectTerms Acinetobacter baumannii
Acinetobacter baumannii - drug effects
Acinetobacter Infections
Acinetobacter Infections - drug therapy
Acinetobacter Infections - microbiology
Anti-Bacterial Agents
Anti-Bacterial Agents - pharmacology
Cathelicidins
Cathelicidins - pharmacology
Drug Resistance, Multiple, Bacterial
Edetic Acid - pharmacology
Endopeptidases
Endopeptidases - chemistry
Endopeptidases - pharmacology
Experimental Therapeutics
Humans
Microbial Sensitivity Tests
Microfluidic Analytical Techniques
Pseudomonadales
Pseudomonas aeruginosa
Pseudomonas aeruginosa - drug effects
Recombinant Fusion Proteins
Recombinant Fusion Proteins - pharmacology
Title Efficacy of Artilysin Art-175 against Resistant and Persistent Acinetobacter baumannii
URI https://www.ncbi.nlm.nih.gov/pubmed/27021321
https://journals.asm.org/doi/10.1128/AAC.00285-16
https://www.proquest.com/docview/1791325882
https://www.proquest.com/docview/1808713537
https://pubmed.ncbi.nlm.nih.gov/PMC4879360
Volume 60
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIhAXBAVKeGlB0Evq4ud6fYxCoQIFBZGi3iyvvW4sESeKk0P4e_wxZrzrtQMtgl4iPzax4_k8j92Zbwh5nThMOHbOLMltbvkRcyxw6pkV2oL5zOe2n2A18vgzOz3zP54H573ez07W0mYtjtMfl9aVXEeqcAzkilWy_yFZ86NwALZBvvAJEobPf5LxCfI_YL92dCfhNNKLlLhlgbkeJBcQ9VeYdVyhk6hzyTHlHUULu0NcVMcXGgmbByLB-fyyKLr-6rBcF_OiJmtCUoGLuh6uLoWbybku3jKT8u9kjg0nVO4sGJ5VYVDzNZ1t0AaUetlhVRhf_sNqCw9suVJT2Xr9w5zEDNNKTV1jGc7g03F3nsJhbT5VpzQAdVYnG3VctGxTXS3NmIUwUTZKKWbkPWWB6n7baG7ViUAjtKuGPV-1h9ImHXb55ebCxRKI4XBU59MGlir77CBnOa-hg0V7ELY7rdE0qYyT8Qhivshj9g1y0w3BgcPMgC8tZT3ctKqD0n-qqb5w-dvuhZGVWl8FvIOkmru7ntIf4c_vWbwdt2h6j9zV8QwdKnDeJz1Z7pNbqsPpdp_cHuvcjX1yOFEs6dsjOm2L_qojekgnLX_69gH51sCaLnJqYE01rKmGNTWwpoAM2sKa7sCaGlg_JGfvT6ajU0u3_7AScOvXlgxCmXGRSbQZSEwIvmbKueOlWQiqRNhRGnhwMBJ-GMjMSYVvJ1nAcu5JLlnkPSJ75aKUjwmNPBFGrmQpczJfeHmS-9znXorxtZcIt09e4ROP9btdxXVo7PIYJBTXEood1ieDRh5xqgn0sY_L9ytGvzGjl4o45opxLxvRxqDZcbkuKeViA_cQRoCGAELgv4wBDYtNNr2wTw4UHMzVGjj1SbgDFDMAmeV3z5TFrGaY14h-cu1vPiV3Wh3wjOytVxv5HLz3tXhRvx2_AIkL79U
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Artilysin+Art-175+against+Resistant+and+Persistent+Acinetobacter+baumannii&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Defraine%2C+Valerie&rft.au=Schuermans%2C+Joris&rft.au=Grymonprez%2C+Barbara&rft.au=Govers%2C+Sander+K.&rft.date=2016-06-01&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=60&rft.issue=6&rft.spage=3480&rft.epage=3488&rft_id=info:doi/10.1128%2FAAC.00285-16&rft_id=info%3Apmid%2F27021321&rft.externalDocID=PMC4879360
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon